Regulatory Requirements for Peptide Sameness Study (FDA & Health Canada) скачать в хорошем качестве

Regulatory Requirements for Peptide Sameness Study (FDA & Health Canada)

Understanding peptide sameness studies is critical for pharmaceutical companies developing generic peptide drugs. Regulatory agencies like the U.S. Food and Drug Administration and Health Canada require strong analytical evidence to prove that a proposed peptide drug is identical to the reference listed drug (RLD) in structure, purity, and biological activity. In this video, we break down the regulatory requirements for peptide sameness studies, including primary structure confirmation, impurity profiling, higher-order structure analysis, and biological activity comparison. These analytical studies are essential because even small differences in peptide sequence or impurities can impact safety, efficacy, or immunogenicity. Regulatory guidance therefore emphasizes advanced analytical characterization and orthogonal testing strategies to demonstrate sameness between a generic peptide and its reference product. If you're working in pharmaceutical R&D, regulatory affairs, analytical chemistry, or peptide drug development, this video provides a clear overview of what regulators expect for peptide sameness evaluation. 📖 Full article on FDA peptide sameness study requirements: https://resolvemass.ca/fda-peptide-sa... #PeptideDrugs #PharmaceuticalRegulations #PeptideAnalysis #GenericDrugs #FDARegulations #HealthCanada #PeptideCharacterization #AnalyticalChemistry #DrugDevelopment #BiotechResearch #PharmaIndustry #RegulatoryAffairs